RNA
NASDAQ HealthcareAvidity Biosciences, Inc. - Common Stock
Biotechnology
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
๐ Market Data
| Price | $13.43 |
|---|---|
| Volume | 168,987 |
| Market Cap | 208.37M |
| RSI (14-Day) | 51.1 |
| 52-Week High | $16.77 |
| 52-Week Low | $11.95 |
| Forward P/E | -3.33 |
| Price / Book | -3.32 |
๐ฏ Investment Strategy Scores
RNA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (60/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find RNA in your text
Paste any article, transcript, or post โ the tool will extract RNA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.